Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893901 | 0.87 | BTK (0.35) | PDGFRAKDRMEN1KMT2AMAPT | |
| SCHEMBL1897756 | 0.78 | KDR (0.49) | PDGFRAKDR | |
| SCHEMBL1897544 | 0.77 | PDGFRA (0.41) | PDGFRAKDRMEN1KMT2APTGS2 | |
| SCHEMBL3504189 | 0.75 | PDGFRA (0.41) | PDGFRAKDRMEN1KMT2ASRD5A2 | |
| SCHEMBL3504192 | 0.75 | PDGFRA (0.41) | PDGFRAKDRMEN1KMT2ASRD5A2 | |
| SCHEMBL14540961 | 0.73 | HTT (0.48) | PDGFRAKDRMEN1KMT2AMAPT | |
| SCHEMBL1897543 | 0.72 | KMT2A (0.44) | PDGFRAKDRMEN1KMT2APTGS2 | |
| SCHEMBL1897540 | 0.72 | KMT2A (0.44) | PDGFRAKDRMEN1KMT2APTGS2 | |
| SCHEMBL1894149 | 0.71 | ALDH1A1 (0.46) | PDGFRAKDRMEN1KMT2ASRD5A2 | |
| SCHEMBL4272426 | 0.70 | TDP1 (0.53) | MEN1KMT2ASRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | PDGFRA 1572/4885KDR 22/4885MEN1 3116/4885 |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | GNG2, GCG, FRG1 | PDGFRA 3135/4885KDR 2782/4885MEN1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.